Results From Halted Islatravir Antiretroviral Trial
Recruitment stopped on the phase 3 trial of the once-daily oral drug islatravir in combination with doravirine, but the study of the investigational new option for HIV continued for the full 48 weeks.
Medscape Medical News
source https://www.medscape.com/viewarticle/995172?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/995172?src=rss
Comments
Post a Comment